Aptose Biosciences announced it has entered into an equity distribution agreement with JonesTrading Institutional Services LLC, as agent. Under the terms of the Equity Distribution Agreement, the Company may, from time to time, issue and sell through the Agent, common shares of the Company through "at-the-market" distributions on the Nasdaq Capital Market. Aptose will determine, at its sole discretion, the time, price and number of Common Shares to be sold under the Offering. In connection with the Offering, Aptose filed a prospectus supplement with the U.S. Securities and Exchange Commission, qualifying the offer and sale of Common Shares having an aggregate offering price of up to $50M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APTO:
- Aptose Biosciences Establishes New At-The-Market Facility
- Aptose Biosciences provides clinical update on tuspetinib, luxeptinib
- Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
